TAIPEI, Taiwan – Astrazeneca plc and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) are collaborating to repurpose a basket of clinical-stage drug candidates provided by the London-based big pharma for possible new therapies targeting Asian-prevalent diseases, using an open innovation model of development.